GKB Ophthalmics share price & results
- Jun 2026
- Jun 2026
Goa-based manufacturer of plastic and glass ophthalmic lenses, sold domestically and through US, UAE, Dubai and South Africa subsidiaries amid rising Chinese import competition.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 33.0 | +2.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 8.0 | +5.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | 6.89 | +15.7 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -3.29 | +1.4 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 29.95 | +12.8 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −6.1% YTD
YTD: ₹65 on 17 Aug 2026 → ₹61.03. High ₹71.52 (8 Sept 2026), low ₹58.61 (22 Oct 2026).
- Previous close
- ₹60.2
- Market cap
- ₹32 Cr
- 52-week range
- ₹58.61 – ₹71.52
- Price to earnings (TTM to Jun 2026)
- 8.79×
- Return on equity (TTM to Jun 2026)
- 6.89%
Overview
- Symbol
- NSE:GKB
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What GKB Ophthalmics Ltd. does
Based on the company's own presentations, annual report and earnings calls.
GKB Ophthalmics manufactures plastic and glass ophthalmic lenses at its Goa (India) facility, which includes multiple manufacturing units (referenced as Unit I and Unit II) producing lenses used in prescription eyewear. It distributes internationally through wholly-owned and step-down subsidiaries: GKB Ophthalmics Products FZE in Sharjah (UAE), Lensco - The Lens Company in New Jersey (USA), Prescription Optical Products LLC in Dubai (which also handles contact lenses), and a newly incorporated Prime Ophthalmics Products PTY in South Africa set up to serve African demand. A separate subsidiary, GSV Ophthalmics Private Limited, was incorporated to produce Hi-Index ophthalmic lenses, but that project has since become financially unviable. The company faces stiff competition from lower-priced Chinese lens imports into India and is pursuing anti-dumping duty relief with authorities.
Segments
- Domestic lens manufacturing
- Overseas subsidiaries - lens trading/distribution
- Hi-Index lens project (GSV Ophthalmics)
- Manufacturing units
- Multiple units (Unit I & Unit II) at Goa, India
- Global subsidiaries
- 5 (UAE, USA, Dubai, South Africa, India)
- Overseas presence
- UAE (Sharjah), USA (New Jersey), Dubai, South Africa
- Permanent employees
- 170 (FY25)
- Quality certification
- ISO 9001:2015 (TUV SUD South Asia)
- Recent capacity investment
- 2 new advanced lens development & coating machines (sourced from Bangalore)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +389% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 26 | 26 | 31 | 32 | 30 | 57 | 30 | 33 |
| Expenses | 26 | 27 | 34 | 32 | 27 | 55 | 27 | 30 |
| Operating profit | -0 | -1 | -3 | 1 | 3 | 2 | 3 | 3 |
| Operating margin | −0.2% | −3.6% | −9.2% | 2.5% | 10.0% | 2.9% | 10.3% | 8.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 1 | -1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| Tax rate | 5.5% | 2.7% | 4.8% | 14.3% | 3.7% | −4.4% | −3.7% | 9.8% |
| Net profit | -1 | -2 | -4 | -1 | 2 | 1 | 1 | 2 |
| EPS (₹ per share) | -2.42 | -4.03 | -7.04 | -2.02 | 3.17 | 0.87 | 0.38 | 2 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 88 | 109 | 149 |
| Expenses | 88 | 112 | 141 |
| Operating profit | 0 | -3 | 9 |
| Other income | 2 | 1 | 0 |
| Interest | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 |
| Profit before tax | -3 | -7 | 3 |
| Net profit | -3 | -7 | 3 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 58 | 58 | 55 | 47 | 48 | 48 |
| Borrowings | 12 | 11 | 11 | 14 | 15 | 12 |
| Other liabilities | 35 | 38 | 43 | 59 | 74 | 68 |
| Total liabilities | 110 | 112 | 114 | 125 | 141 | 132 |
| Fixed assets | 23 | 19 | 18 | 17 | 17 | 15 |
| Capital work in progress | 3 | 4 | 4 | 4 | 4 | 4 |
| Investments | 2 | 2 | 2 | 2 | 2 | 2 |
| Other assets | 82 | 87 | 91 | 102 | 119 | 111 |
| Total assets | 110 | 112 | 114 | 125 | 141 | 132 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 7 | 5 | -3 | 4 | -3 | -4 |
| Cash from investing | -17 | -4 | 1 | -2 | 3 | 9 |
| Cash from financing | 3 | -2 | -2 | -2 | 1 | -6 |
| Net cash flow | -7 | 0 | -4 | 1 | 0 | 0 |
| Free cash flow | 1 | 0 | -2 | 2 | -6 | -5 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 125 | 100 | 134 | 117 | 85 | 110 |
| Inventory days | 349 | 307 | 298 | 245 | 250 | 189 |
| Days payable | 234 | 208 | 183 | 202 | 195 | 195 |
| Cash conversion cycle | 239 | 199 | 249 | 160 | 141 | 104 |
| Working capital days | 117 | 105 | 135 | 97 | 78 | 78 |
| Return on capital employed | 3.0% | 4.0% | 2.0% | −1.0% | −6.0% | 11.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 51.15% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 51.15%
- Foreign institutions 1.79%
- Domestic institutions 0.00%
- Public 47.07%
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 1.01% held
- +0.14 pp 4.82% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of GKB Ophthalmics Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 17.91% | unchanged | |
| 8.39% | unchanged | |
| 8.09% | unchanged | |
| 5.97% | unchanged | |
| 5.97% | unchanged | |
| 5.54% | unchanged | |
| 4.82% | +0.14 pp | |
| 4.81% | unchanged | |
| 3.97% | unchanged | |
| 3.31% | unchanged | |
| FPI fund | 1.79% | unchanged |
| 1.40% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for GKB Ophthalmics Ltd.
Free account: one company. Everything above stays public.
Write why you follow GKB Ophthalmics Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse GKB Ophthalmics Ltd.
Guides on how to read this kind of business and the numbers that matter.